A New CYP2E1 Inhibitor, 12-Imidazolyl-1-dodecanol, Represents a Potential Treatment for Hepatocellular Carcinoma

Figure 7

HepG2 cell-transplanted mice in a xenograft model. (a) Body-weight dynamics from animal study one. (b) Body-weight dynamics from animal study two. Increased body weights of the treated mice, compared to the control groups of both studies. (c) Tumour volumes from animal study one. (d) Tumour volumes from animal study two. Markedly reduced tumour volumes were observed in treated mice compared to the control groups, in both studies. (e) Tumour volume: bw ratios from animal study one. (f) Tumour volume: bw ratios from animal study two. The results are comparable to those described above. (g) Final tumour masses from animal study one. (h) Final tumour masses from animal study two. Over a two-fold decrease in the final tumour masses was observed in both studies. The significance values determined as the “simple main effect of time” are shown below the group designations. The results are depicted as individual values of the dependent variable (i.e., the measured pathological parameters) grouped around the mean value, which is depicted with a horizontal red line. Statistical calculations were performed based on two-way mixed ANOVA, followed by Bonferroni’s post hoc test. In all cases, the significance levels were (significant), (highly significant), or (very highly significant). Dose-dependent effects of I-ol were calculated by determining Pearson’s correlation coefficient (r) and performing linear-regression analysis (adjusted R²), with the following statistical parameters: (significant), (highly significant), and (very highly significant).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)